Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Rapamycin Press LLC dba Impact Journals is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack... This malicious action will be reported to the FBI.

Search Oncotarget

32 results found — showing 21–32

Sort Year Per page

Low level phosphorylation of histone H2AX on serine 139 (Î³H2AX) is not associated with DNA double-strand breaks Research Paper

Paulina Rybak, Agnieszka Hoang, Lukasz Bujnowicz, Tytus Bernas, Krzysztof Berniak, MirosÅ‚aw ZarÄ™bski, Zbigniew Darzynkiewicz, Jerzy Dobrucki

Published Jul 6, 2016 · Vol. 7, No. 31 · pp. 49574-49587

Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis Research Paper

Chien-Ju Lin, Yi-Ling Lin, Frank Luh, Yun Yen, Ruei-Ming Chen

Published Jun 7, 2016 · Vol. 7, No. 27 · pp. 42408-42421

Î²2-spectrin depletion impairs DNA damage repair Priority Research Paper

Nobuo Horikoshi, Raj K. Pandita, Kalpana Mujoo, Shashank Hambarde, Dharmendra Sharma, Abid R. Mattoo, Sharmistha Chakraborty, Vijaya Charaka, Clayton R. Hunt, Tej K. Pandita

Published May 27, 2016 · Vol. 7, No. 23 · pp. 33557-33570

Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer Priority Research Paper

Raghavendra A. Shamanna, Huiming Lu, Deborah L. Croteau, Arvind Arora, Devika Agarwal, Graham Ball, Mohammed A. Aleskandarany, Ian O. Ellis, Yves Pommier, Srinivasan Madhusudan, Vilhelm A. Bohr

Published Mar 3, 2016 · Vol. 7, No. 12 · pp. 13269-13284

Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery Research Paper

Kaushlendra Tripathi, Chinnadurai Mani, David W Clark, Komaraiah Palle

Published Feb 8, 2016 · Vol. 7, No. 11 · pp. 12537-12553

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer Research Paper

Changping Wu, Xin Jin, Jing Yang, Yinhui Yang, Yundong He, Liya Ding, Yunqian Pan, Shuai Chen, Jingting Jiang, Haojie Huang

Published Dec 7, 2015 · Vol. 7, No. 3 · pp. 3440-3452

Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design Research Paper

Andrew J. Massey, Stephen Stokes, Helen Browne, Nicolas Foloppe, AndreÃ¡ Fiumana, Simon Scrace, Mandy Fallowfield, Simon Bedford, Paul Webb, Lisa Baker, Mark Christie, Martin J. Drysdale, Mike Wood

Published Sep 30, 2015 · Vol. 6, No. 34 · pp. 35797-35812

Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents Research Paper

Chenchu Lin, Hanlin Zeng, Junyan Lu, Zuoquan Xie, Wenyi Sun, Cheng Luo, Jian Ding, Shengtao Yuan, Meiyu Geng, Min Huang

Published May 4, 2015 · Vol. 6, No. 24 · pp. 20578-20591

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins Research Paper

Valentina Zuco, Michelandrea De Cesare, Nadia Zaffaroni, Cinzia Lanzi, Giuliana Cassinelli

Published Mar 12, 2015 · Vol. 6, No. 11 · pp. 8736-8749

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway Research Paper

Annalisa Conti, Maria Teresa Majorini, Richard Elliott, Alan Ashworth, Christopher J. Lord, Carlotta Cancelliere, Alberto Bardelli, Pierfausto Seneci, Henning Walczak, Domenico Delia, Daniele Lecis

Published Mar 12, 2015 · Vol. 6, No. 13 · pp. 10994-11008

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients Clinical Research Papers

Corinna Eichelser, Isabel StÃ¼ckrath, Volkmar MÃ¼ller, Karin Milde-Langosch, Harriet Wikman, Klaus Pantel, Heidi Schwarzenbach

Published Oct 7, 2014 · Vol. 5, No. 20 · pp. 9650-9663

A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Research Paper

Francesco Sottile, Ilaria Gnemmi, Sandra Cantilena, Walter C. D'Acunto, Arturo Sala

Published May 19, 2012 · Vol. 3, No. 5 · pp. 535-545

Keywords: Neuroblastoma, chemotherapeutic drug, oncogene, transcription

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Low level phosphorylation of histone H2AX on serine 139 (Î³H2AX) is not associated with DNA double-strand breaks Research Paper

Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis Research Paper

Î²2-spectrin depletion impairs DNA damage repair Priority Research Paper

Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer Priority Research Paper

Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery Research Paper

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer Research Paper

Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design Research Paper

Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents Research Paper

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins Research Paper

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway Research Paper

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients Clinical Research Papers

A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Low level phosphorylation of histone H2AX on serine 139 (Î³H2AX) is not associated with DNA double-strand breaks Research Paper

Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis Research Paper

Î²2-spectrin depletion impairs DNA damage repair Priority Research Paper

Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer Priority Research Paper

Rad18 is required for functional interactions between FANCD2, BRCA2, and Rad51 to repair DNA topoisomerase 1-poisons induced lesions and promote fork recovery Research Paper

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer Research Paper

Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design Research Paper

Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents Research Paper

PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins Research Paper

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway Research Paper

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients Clinical Research Papers

A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Research Paper